A Unique Portfolio of Biomarker Discovery Tools, Proprietary Biomarkers & Quantitative Multiplexed Assays for Cancer – Applications in Drug Development, Diagnosis, Treatment Selection & Prognosis
Cancer is a leading cause of mortality globally, accounting for approximately 8.2 million deaths worldwide in 2012. The estimated number of cancer cases worldwide will increase by 70% in the next 2 decades.
Unlike normal cells, cancer cells lose the ability to control their cell cycle and continue growing unchecked. In most forms of cancer deregulation of the cell signaling pathways that are intimately involved in regulating and governing cell cycle status leads to altered response to growth stimuli. In today’s era of personalized medicine clinicians need to type cancers based on which pathways are activated and which are inactive to aid selection of the right type of modern anti-cancer drugs which specifically target and shut down overactive pathways.
Many of the more recently approved cancer treatments target either the cell surface receptors at the head of these signaling pathways, or the intermediate phosphoproteins and kinases in the pathway signaling cascades. Understanding the phosphoprotein activation state of key signaling molecules in tumor cells can yield critical information on the type, stage and status of those cells, aiding in the diagnosis, prognosis and treatment of an individual’s disease.
Cancer cells often express proteins that differentiate themselves from normal cells – these proteins can be used as biomarkers to monitor disease progression.
As with many diseases, cancer has an underlying genetic component, but it is the proteome content that provides the window on the immediate status and activity of both benign and malignant cells. Proteome Sciences has developed several quantitative multiplexed mass spectrometry assays targeting key signaling molecules implicated in malignant disease processes.
Multiplexed signaling pathway assays for discovery and clinical applications in cancer
Proteome Sciences is focusing on two key areas of signalling pathways in cancer research; a targeted assessment of signalling pathways leading to endocrine resistance in breast cancer
and a global measurement of signaling pathways (Our SysQuant® Global Phosphorylation Assay
) associated with cancers. Signalling receptor molecules, including steroid hormone receptors, and their downstream kinases and phosphoproteins can be used as key biomarkers to study, diagnose and track disease.
to learn more about our extensive PS Biomarker ServicesTM
for Cancer or to arrange a consultation with our scientists.